XML 122 R52.htm IDEA: XBRL DOCUMENT v3.21.2
Shareholders' Equity and Redeemable Non-Controlling Interest - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Dec. 27, 2019
Dec. 26, 2019
Mar. 31, 2021
Sep. 30, 2020
May 31, 2020
Apr. 30, 2020
Mar. 31, 2020
Jan. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Mar. 31, 2021
Mar. 31, 2020
Jun. 30, 2021
May 31, 2021
Feb. 29, 2020
Class of Stock [Line Items]                              
Warrant exercise price per share                           $ 0.01  
Earnout shares                     (i) during any Trading Period prior to March 31, 2023, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price of at least $17.50 per share; and (ii) during any Trading Period prior to March 31, 2025, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price of at least $31.50 per share.        
Common stock issued     222,669,799 17,547,938     214,879,058       222,669,799 214,879,058 222,669,799 17,547,938  
Net proceeds of common stock                     $ 0 $ 999,193      
Convertible Notes Payable [Member]                              
Class of Stock [Line Items]                              
Conversion of stock , share converted                     2,500,000        
Carrying amount of the convertible promissory     $ 35,600               $ 35,600        
Common Stock [Member]                              
Class of Stock [Line Items]                              
Public offering shares of common stock                     7,202,917 26,952,143      
Underwritten Public Offering [Member] | Common Stock [Member]                              
Class of Stock [Line Items]                              
Public offering shares of common stock       380,000   1,034,483                  
Net proceeds of common stock       $ 12,500   $ 15,000                  
Sumitomo Transaction Agreement [Member] | Roivant Equity Repurchase [Member]                              
Class of Stock [Line Items]                              
Offer to repurchase common stock held by each holder   11.23%                          
Common stock per share   $ 37.10                          
Description of share repurchase offer                     The offers included (i) an offer to repurchase up to approximately 11.23% of the common stock held by each holder (and its affiliates) of the Company’s common stock as of December 26, 2019, at a price per share of $37.10 representing fair value of the common stock, (ii) an offer to purchase vested stock options whose fair market value (as determined as of December 27, 2019) was less than or equal to the fair market value of approximately 11.23% of the earliest-granted of such holder’s outstanding vested and unvested stock options, at a purchase price equal to such vested option’s fair market value, and (iii) an offer to holders of performance restricted stock units (“pRSUs”) to surrender 100% of their existing pRSUs in exchange for newly issued performance stock options and capped value appreciation rights. The offer to the holders of pRSUs included an offer by the Company to immediately purchase approximately 11.23% of the newly issued performance stock options and capped value appreciation rights for cash.        
Maximum | Sumitomo Transaction Agreement [Member] | Roivant Equity Repurchase [Member]                              
Class of Stock [Line Items]                              
Equity securities authorized for repurchase                             $ 1,000,000
Immunovant, Inc [Member]                              
Class of Stock [Line Items]                              
Earnout shares                     20,000,000        
Immunovant, Inc [Member] | Convertible Notes Payable [Member]                              
Class of Stock [Line Items]                              
Conversion of stock , share converted                     7,156,495        
Immunovant, Inc [Member] | Warrant                              
Class of Stock [Line Items]                              
Number of outstanding warrants     5,719,145   5,750,000           5,719,145        
Warrant exercise price per share     $ 11.50   $ 11.50           $ 11.50        
Number of exercisable outstanding warrants     11,438,290   11,500,000           11,438,290        
Proceeds of warrants                     $ 65,800        
Warrants cancellation                     $ 61,710        
Immunovant, Inc [Member] | Underwritten Public Offering [Member] | Common Stock [Member]                              
Class of Stock [Line Items]                              
Common stock per share       $ 33.00   $ 14.50                  
Public offering shares of common stock       6,060,606   9,613,365                  
Net proceeds of common stock       $ 188,100   $ 131,000                  
Health Sciences [Member] | Common Stock [Member]                              
Class of Stock [Line Items]                              
Stock acquired related to business acquisition                   42,080,376          
Health Sciences [Member] | Series A 1 Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Stock acquired related to business acquisition                   10,000          
Sumitomo [Member]                              
Class of Stock [Line Items]                              
Number of shares transferred 26,952,143               26,952,143            
Share price                 $ 37.10            
Net proceeds from sale of stock                 $ 999,200     $ 2,900,000      
Sumitomo [Member] | Maximum                              
Class of Stock [Line Items]                              
Equity securities authorized for repurchase                 $ 1,000,000            
Cytovant Science HK Ltd [Member] | Series A 1 Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Number of shares transferred             20,085,301                
Share price             $ 1.17         $ 1.17      
Net proceeds from sale of stock             $ 22,500                
Health Sciences [Member]                              
Class of Stock [Line Items]                              
Number of outstanding warrants                   11,500,000          
Warrant exercise price per share                   $ 11.50          
Health Sciences [Member] | Common Stock [Member]                              
Class of Stock [Line Items]                              
Number of outstanding warrants                   5,750,000          
Health Sciences [Member] | Immunovant, Inc [Member]                              
Class of Stock [Line Items]                              
Percentage of common stock acquired related to business acquisition                   100.00%          
Cash as a result of the Business Combination                   $ 111,000          
Proceeds related to common stock purchase by RSL                   $ 5,100          
Immunovant Sciences Ltd [Member]                              
Class of Stock [Line Items]                              
Common stock issued       20,000,000 20,000,000                    
Immunovant Sciences Ltd [Member] | Restricted Stock [Member]                              
Class of Stock [Line Items]                              
Restricted shares vested       1,800,000 1,800,000                    
Immunovant Sciences Ltd [Member] | Convertible Notes Payable [Member]                              
Class of Stock [Line Items]                              
Conversion of stock , share converted                     3,499,995        
Sinovant Inc [Member]                              
Class of Stock [Line Items]                              
Annualized return rate     12.00%                        
Preferred stock purchase price per share               $ 12.26              
Preferred stock purchase price               $ 132,900              
Repurchase of redeemable noncontrolling interest               $ 77,800